Hospital Injectable Products · LP-203
Thiamine (Vitamin B1) Injection
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-203Hospital Injectable Products
- Generic identity
- Thiamine (Vitamin B1)Injection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-203
- Generic ingredient
- Thiamine (Vitamin B1)
- Dosage form
- Injection
- Proposed strength
- 100 mg/mL
- Proposed pack
- Ampoule 1 mL; carton 10 ampoules
- Portfolio category
- Hospital Injectable Products
About Thiamine (Vitamin B1)
Thiamine is vitamin B1, an essential nutrient involved in carbohydrate metabolism and normal neurological and cardiac function. Deficiency can have serious consequences and occurs in different nutritional and medical settings. Oral and injectable thiamine serve different purposes depending on urgency, absorption and the clinical condition. An oral tablet should not be assumed to substitute for parenteral treatment when an acute deficiency syndrome is suspected.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Assessment can involve poor nutritional intake, malabsorption or other circumstances associated with deficiency. Acute neurological symptoms in a person at risk require urgent medical evaluation rather than reliance on a supplement catalogue. A clinician determines whether oral or parenteral treatment is appropriate and whether associated nutritional or electrolyte problems need attention. This page does not provide an emergency protocol or confirm a locally authorized indication for the proposed presentation.
Important safety considerations
Thiamine is often well tolerated, but hypersensitivity can occur. Parenteral administration can rarely produce serious allergic reactions and requires an appropriate monitored setting with trained staff. Local injection reactions are possible. Persistent neurological or cardiovascular symptoms require evaluation even if thiamine has been given. The product-specific excipients and route must be checked, especially in vulnerable patients or anyone with previous reactions to injectable vitamin preparations.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The oral and injectable entries require distinct specifications. Confirm thiamine salt, amount per tablet or millilitre, injection route and preservative content. An ampoule size or vitamin designation does not establish stability, dilution compatibility or a storage requirement.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Assess clinical urgency, nutritional history, neurological findings and the appropriate route. Verify the actual product and any monitoring requirements under relevant local guidance.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Thiamine (Vitamin B1)
- Dosage form / presentation
- Injection
- Catalogue strength
- 100 mg/mL
- Catalogue pack
- Ampoule 1 mL; carton 10 ampoules
- Portfolio category
- Hospital Injectable Products
Layer 02
Unresolved product-specific fields
- The catalogue establishes thiamine injection at 100 mg/mL in a 1 mL ampoule but does not state the thiamine salt, authorised route, preservative system, compatibility or administration protocol.
- The external thiamine-hydrochloride label illustrates formulation-specific controls only and does not establish the Luang record as hydrochloride.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- NIH ODS: Thiamin — Health Professional Fact Sheetgovernment scientific fact sheet
- DailyMed: thiamine hydrochloride injection — external reference labelgovernment-hosted external product label
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Sterile product specification confirming exact active chemical form, concentration or vial content, container/fill, authorised route(s), excipients/preservatives and preparation/compatibility controls.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-203, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
- NIH ODS: Thiamin — Health Professional Fact Sheet
- DailyMed: thiamine hydrochloride injection — external reference label
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-203.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.